

Oral presentation

Open Access

Microglial downregulation in a double transgenic mouse model associated with early-onset Alzheimer's disease (AD) after intraventricular implantation of alginate encapsulated Glukagon-like-peptide-1 (GLP-1) producing human mesenchymal stem-cells

Kathrin Harmening¹, Anna Heile¹, Miles Miller², Conrad E Johanson², Christine Wallrapp³, Thomas Brinker¹, Gerald D Silverberg² and Petra M Klinge^{*2}

Address: ¹International Neuroscience Institute GmbH, Rudolf-Pichlmayr-Str. 4, D-30625 Hannover, Germany, ²Department of Clinical Neuroscience, Alpert Medical School at Brown University, Rhode Island Hospital, 593 Eddy Street, Providence, Rhode Island, 02903 USA and ³Cellmed AG, Industriestr. 19, 63755 Alzenau, Germany

Email: Petra M Klinge* - pmklinge@gmail.com

* Corresponding author

from 53rd Annual Meeting of the Society for Research into Hydrocephalus and Spina Bifida
Belfast, UK. 24-27 June 2009

Published: 27 November 2009

Cerebrospinal Fluid Research 2009, 6(Suppl 2):S15 doi:10.1186/1743-8454-6-S2-S15

This abstract is available from: <http://www.cerebrospinalfluidresearch.com/content/6/S2/S15>

© 2009 Harmening et al; licensee BioMed Central Ltd.

Background

GLP-1 peptide is an endogenous insulinotropic peptide. GLP-1 receptors are expressed throughout the brains of rodents and humans. Intracerebroventricular GLP-1 administration reduced the levels of amyloid-beta peptide (A β) in diabetic mice and protected cultured hippocampal neurons against A β and iron induced stress suggesting that GLP-1 can modify amyloid precursor protein (APP) processing and protect against oxidative injury [1]. In the double transgenic mice model associated with early-onset AD, the effect of GLP-1 secreting human mesenchymal stem cells (hMSC) on A β 40/42 load, A β associated gliosis and microglial response were investigated in the present study.

Materials and methods

Alginate microcapsules (CellBeads®) containing "native" (CB085) or GLP-1 transfected hMSCs (CB087) were stereotactically implanted into the right ventricle of double transgenic mice mutant expressing APP and presenilin-1 protein (APP^{swe}, PSEN1^{dEG}; JACKSON LAB) at 27 weeks

of age (n = 14 each). After 8 weeks of implantation (i.e. 35 weeks of age), brains of 4 animals per group were processed for histological assessment using Antibodies against A β 40/42 (polyclonal; US BIOLOGICAL), glial fibrillary acidic protein (GFAP polyclonal, DAKO) and the microglial marker CD11b (monoclonal; BIOMOL). The remaining brains were used for A β 40/42 ELISA. N= 7 35-36 weeks old Tg-mice provided the age-matched early-onset AD controls.

Results

Total counts of A β 40/42 positively stained plaques assessed in the frontal cortex were reduced in the animals with GLP-1 transfected CellBeads® implants when compared to the "native" stem-cell group and the control: 107 \pm 24 (GLP-1 hMSCs) vs. 165 \pm 44 ("native" hMSCs) vs. 140 (control, n = 1); p = 0.07 (t-test of GLP-1 vs. "native" hMSCs). Likewise, the number of reactive astrocytes (> three GFAP positively stained processes) measured in the dentate gyrus of the hippocampus showed a tendency towards a lower count in GLP-1 CellBeads® mice. Morpho-

metric analysis of CD11b positively stained particles per cortical area (%) showed most striking evidence in group differences: animals with GLP-1 transfected CellBeads® showed a significant reduction of microglial immunoreactivity against age-matched AD control: $0.28 \pm 0.14\%$ vs. $0.58 \pm 0.05\%$ ($p = 0.02$, t-test). "Native" CellBeads® showed a reduced but not significant change in the microglial response.

Conclusion

GLP-1 producing stem cells encapsulated in alginate have lowered A β 40/42 load in a mouse model of early-onset AD, which corresponded to a significant down-regulation of specific microglial-type changes in that model.

References

1. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH: **Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (A β) levels and protects hippocampal neurons from death induced by A β and iron.** *J Neurosci Res* 2003, **72**:603-612.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

